- Home
- IONS
as of 01-23-2026 3:40pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 13.5B | IPO Year: | 1991 |
| Target Price: | $83.64 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $86.15 | Next Earning Date: | 02-18-2026 |
| Revenue: | $966,957,000 | Revenue Growth: | 20.41% |
| Revenue Growth (this year): | 29.67% | Revenue Growth (next year): | -0.17% |
AI-Powered IONS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
EVP, Chief Human Resources Ofc
Avg Cost/Share
$81.34
Shares
3,977
Total Value
$323,490.37
Owned After
22,541
SEC Form 4
EVP, Chief Business Officer
Avg Cost/Share
$75.77
Shares
16,112
Total Value
$1,220,552.94
Owned After
4,772
EVP Research
Avg Cost/Share
$75.66
Shares
9,933
Total Value
$748,383.09
Owned After
318
Chief Executive Officer
Avg Cost/Share
$74.82
Shares
44,034
Total Value
$3,294,623.88
Owned After
224,683
SEC Form 4
EVP, Chf Clinical Develop Ofcr
Avg Cost/Share
$75.59
Shares
9,302
Total Value
$703,138.18
Owned After
63,890
SEC Form 4
EVP, Chief Scientific Officer
Avg Cost/Share
$75.15
Shares
17,954
Total Value
$1,349,243.10
Owned After
94,757
EVP, Corp and Development Ops
Avg Cost/Share
$75.11
Shares
16,960
Total Value
$1,273,865.60
Owned After
60,435
EVP CLO & General Counsel
Avg Cost/Share
$75.84
Shares
9,191
Total Value
$697,045.44
Owned After
66,171
SEC Form 4
EVP, Finance & CFO
Avg Cost/Share
$75.22
Shares
12,922
Total Value
$971,992.84
Owned After
126,307
SEC Form 4
EVP, Chf GL Pdt Str Ofcr
Avg Cost/Share
$75.96
Shares
1,823
Total Value
$138,475.08
Owned After
16,389
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Devers Shannon L. | IONS | EVP, Chief Human Resources Ofc | Jan 22, 2026 | Sell | $81.34 | 3,977 | $323,490.37 | 22,541 | |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Jan 16, 2026 | Sell | $75.77 | 16,112 | $1,220,552.94 | 4,772 | |
| Swayze Eric | IONS | EVP Research | Jan 16, 2026 | Sell | $75.66 | 9,933 | $748,383.09 | 318 | |
| Monia Brett P | IONS | Chief Executive Officer | Jan 16, 2026 | Sell | $74.82 | 44,034 | $3,294,623.88 | 224,683 | |
| Schneider Eugene | IONS | EVP, Chf Clinical Develop Ofcr | Jan 16, 2026 | Sell | $75.59 | 9,302 | $703,138.18 | 63,890 | |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Jan 16, 2026 | Sell | $75.15 | 17,954 | $1,349,243.10 | 94,757 | |
| Birchler Brian | IONS | EVP, Corp and Development Ops | Jan 16, 2026 | Sell | $75.11 | 16,960 | $1,273,865.60 | 60,435 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Jan 16, 2026 | Sell | $75.84 | 9,191 | $697,045.44 | 66,171 | |
| HOUGEN ELIZABETH L | IONS | EVP, Finance & CFO | Jan 16, 2026 | Sell | $75.22 | 12,922 | $971,992.84 | 126,307 | |
| Jenne Kyle | IONS | EVP, Chf GL Pdt Str Ofcr | Jan 16, 2026 | Sell | $75.96 | 1,823 | $138,475.08 | 16,389 |
Compare IONS vs Leading Stocks
See how IONS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.